Xencor has dosed the first healthy volunteer in a Phase 1/2 study of XmAb942, a high-potency, extended half-life anti-TL1A antibody, for inflammatory bowel disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.